GenSight Biologics S.A. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was EUR 7.7 million compared to EUR 7.4 million a year ago. Net loss was EUR 28.6 million compared to EUR 34 million a year ago. Basic loss per share from continuing operations was EUR 0.63 compared to EUR 0.97 a year ago.